Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2281
mi
from 91732
Washington,
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Georgetown University
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2281
mi
from 91732
Washington DC,
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Howard University
2281
mi
from 91732
Washington DC,
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2135
mi
from 91732
Jacksonville, FL
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Mayo Clinic, Jacksonville
2135
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2135
mi
from 91732
Tampa, FL
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of South Florida
2135
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1726
mi
from 91732
Chicago, IL
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Rush University Medical Center
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1339
mi
from 91732
Kansas City, KA
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of Kansas
1339
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1881
mi
from 91732
Lexington, KY
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of Kentucky
1881
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2301
mi
from 91732
Baltimore, MD
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1932
mi
from 91732
Ann Arbor, MI
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1524
mi
from 91732
Rochester, MN
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
217
mi
from 91732
Las Vegas, NV
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Cleveland Clinic Lou Ruvo Center for Brain Health
217
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2435
mi
from 91732
New York, NY
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Columbia University
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2435
mi
from 91732
New York, NY
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Mount Sinai School of Medicine
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2433
mi
from 91732
New York, NY
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
New York University
2433
mi
from 91732
New York, NY
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2244
mi
from 91732
Rochester, NY
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Univ of Rochester Medical Center
2244
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2036
mi
from 91732
Cleveland, OH
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Case Western Reserve Univ
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2373
mi
from 91732
Philadelphia, PA
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Univ of Pennsylvania
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
2184
mi
from 91732
Charleston, SC
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Medical University of South Carolina
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1225
mi
from 91732
Dallas, TX
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of Texas Southwestern Medical Center
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
1357
mi
from 91732
Houston, TX
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
943
mi
from 91732
Seattle, WA
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of Washington
943
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
2302
mi
from 91732
West Palm Beach, FL
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Premiere Research Institute
2302
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
1881
mi
from 91732
Lexington, KY
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
University of Kentucky
1881
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
1818
mi
from 91732
Louisville, KY
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Norton Healthcare
1818
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
2575
mi
from 91732
Brookline, MA
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Boston Center for Memory
2575
mi
from 91732
Brookline, MA
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
2203
mi
from 91732
Durham, NC
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Duke University
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
2373
mi
from 91732
Philadelphia, PA
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
Univ of Pennsylvania
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated:  12/26/2012
2468
mi
from 91732
Bennington, VT
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
Status: Enrolling
Updated: 12/26/2012
The Memory Clinic
2468
mi
from 91732
Bennington, VT
Click here to add this to my saved trials
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  1/4/2013
343
mi
from 91732
Phoenix, AZ
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 1/4/2013
Banner Alzheimer Institute
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  1/4/2013
2124
mi
from 91732
St Petersburg, FL
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 1/4/2013
Meridien Research
2124
mi
from 91732
St Petersburg, FL
Click here to add this to my saved trials
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status: Enrolling
Updated:  1/4/2013
2319
mi
from 91732
Hallandale Beach, FL
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Status: Enrolling
Updated: 1/4/2013
MD Clinical
2319
mi
from 91732
Hallandale Beach, FL
Click here to add this to my saved trials
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808
Status: Enrolling
Updated:  2/15/2013
33
mi
from 91732
Irvine, CA
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808
Status: Enrolling
Updated: 2/15/2013
University of California, Irvine
33
mi
from 91732
Irvine, CA
Click here to add this to my saved trials
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
A Phase 0, Open Label, Non-randomized, Multi-center Exploratory and Safety Study of [F-18]T807
Status: Enrolling
Updated:  2/15/2013
33
mi
from 91732
Irvine, CA
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
A Phase 0, Open Label, Non-randomized, Multi-center Exploratory and Safety Study of [F-18]T807
Status: Enrolling
Updated: 2/15/2013
University of California, Irvine
33
mi
from 91732
Irvine, CA
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
209
mi
from 91732
Fresno, CA
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
209
mi
from 91732
Fresno, CA
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
21
mi
from 91732
Long Beach, CA
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
356
mi
from 91732
San Francisco, CA
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2487
mi
from 91732
Hamden, CT
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2487
mi
from 91732
Hamden, CT
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2310
mi
from 91732
Delray Beach, FL
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2310
mi
from 91732
Delray Beach, FL
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2185
mi
from 91732
Orlando, FL
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2185
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2133
mi
from 91732
Tampa, FL
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2133
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2304
mi
from 91732
West Palm Beach, FL
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2304
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
1711
mi
from 91732
Elk Grove Village, IL
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
1711
mi
from 91732
Elk Grove Village, IL
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2425
mi
from 91732
Staten Island, NY
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2425
mi
from 91732
Staten Island, NY
Click here to add this to my saved trials
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated:  3/6/2013
2468
mi
from 91732
Bennington, VT
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
2468
mi
from 91732
Bennington, VT
Click here to add this to my saved trials
Metformin in Amnestic Mild Cognitive Impairment
Metformin in the Prevention of Alzheimer's Disease
Status: Enrolling
Updated:  3/13/2013
2432
mi
from 91732
New York, NY
Metformin in Amnestic Mild Cognitive Impairment
Metformin in the Prevention of Alzheimer's Disease
Status: Enrolling
Updated: 3/13/2013
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease
Status: Enrolling
Updated:  3/14/2013
554
mi
from 91732
American Fork, UT
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
554
mi
from 91732
American Fork, UT
Click here to add this to my saved trials
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  3/27/2013
25
mi
from 91732
Los Angeles, CA
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 3/27/2013
Pfizer Investigational Site
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  3/27/2013
2307
mi
from 91732
Atlantis, FL
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 3/27/2013
Pfizer Investigational Site
2307
mi
from 91732
Atlantis, FL
Click here to add this to my saved trials
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  3/27/2013
1918
mi
from 91732
Atlanta, GA
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 3/27/2013
Pfizer Investigational Site
1918
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  3/27/2013
2305
mi
from 91732
Baltimore, MD
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 3/27/2013
Pfizer Investigational Site
2305
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials